While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

GSK (LSE: GSK) has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Johnson & Johnson (NYSE: JNJ) has gone big early doors this year in the world of pharma M&A. The US healthcare giant ...

The Indian pharmaceutical market (IPM) recorded an 8.7% year-on-year (YoY) growth in January 2025, reaching a monthly value ...

Astex Pharmaceuticals has been celebrating a very successful first 25 years following a visit from Science minister Patrick ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 11.11%, which has investors questioning if this is right time ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Budget 2025: Seeks to further amend notification No. 16/2017-Customs, dated the 20th April, 2017 so to exempt certain drugs for supply under Patient Assistance Programme run by specified ...